This is an observational study in patients with non-valvular atrial fibrillation (NVAF) presenting to the hospital with a first acute ischemic stroke based on existing data recorded in the SITS International Registry (located in Sweden) by physicians in several European countries, such as Italy, United Kingdom, Czech Republic, Sweden, Germany, Poland, Spain, Finland, Portugal, Slovakia, Denmark, Estonia, Norway Belgium, Hungary, Slovenia, Croatia, Austria, Lithuania, France, Greece, Netherlands, Ireland, Ukraine and Iceland.
The aim of this study is to explore the current real world use of dabigatran for stroke prevention in NVAF patients in the post-stroke setting. Secondary data from eligible European patients registered in the SITS registry will be considered; countries of origin are not known a priori.
- Dabigatran (Pradaxa)Drug
Other Names: Pradax (Canada)/ Pradaxa (USA and rest of world) Intervention Desc: Oral anticoagulant (NOAC) thrombin inhibitor ARM 1: Kind: Experimental Label: Acute ischemic stroke Description: Non-valvular atrial fibrillation patients hospitalized with an acute ischemic stroke
|Type||Measure||Time Frame||Safety Issue|
|Primary||timing of dabigatran treatment initiation after a first ever ischaemic stroke (index event) in NVAF patients||At Discharge and at 3 months after index event|
|Secondary||Description of baseline characteristics for patients treated with dabigatran according to time of dabigatran initiation||At index stroke date or shortly after (baseline)|
|Secondary||Description of self-reported factors important for physician's decision when to initiate dabigatran and which dabigatran dose is used in the post-ischemic stroke setting for secondary prevention of stroke and safety in NVAF||At index stroke date or shortly after (baseline)|